47 related articles for article (PubMed ID: 7905784)
1. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix.
Mitra AB; Murty VV; Pratap M; Sodhani P; Chaganti RS
Cancer Res; 1994 Feb; 54(3):637-9. PubMed ID: 7905784
[TBL] [Abstract][Full Text] [Related]
2. Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
Nasioudis D; Gysler S; Latif N; Cory L; Giuntoli RL; Kim SH; Simpkins F; Martin L; Ko EM
Gynecol Oncol; 2024 Jan; 180():1-5. PubMed ID: 38029652
[TBL] [Abstract][Full Text] [Related]
3. HER2 Positive Gastric Carcinomas and Their Clinico-Pathological Characteristics.
Ognjenovic L; Trajkovski G; Gjoshev S; Shumkovski A; Dzambaz D; Hadzi-Manchev D; Volcevski G; Fildishevski I; Nikolova D; Petrushevska G; Janevska V; Janevski V
Open Access Maced J Med Sci; 2018 Jul; 6(7):1187-1192. PubMed ID: 30087720
[TBL] [Abstract][Full Text] [Related]
4. Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence
Chae YK; Arya A; Chiec L; Shah H; Rosenberg A; Patel S; Raparia K; Choi J; Wainwright DA; Villaflor V; Cristofanilli M; Giles F
Oncotarget; 2017 Nov; 8(59):100863-100898. PubMed ID: 29246028
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer.
Lu M; Wang T; He M; Cheng W; Yan T; Huang Z; Zhang L; Zhang H; Zhu W; Zhu Y; Liu P
Oncotarget; 2017 Apr; 8(14):23008-23019. PubMed ID: 28160563
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition.
Huang D; Duan H; Huang H; Tong X; Han Y; Ru G; Qu L; Shou C; Zhao Z
Sci Rep; 2016 Feb; 6():20502. PubMed ID: 26846307
[TBL] [Abstract][Full Text] [Related]
7. Amplification of Cellular Oncogenes in Solid Tumors.
Bagci O; Kurtgöz S
N Am J Med Sci; 2015 Aug; 7(8):341-6. PubMed ID: 26417556
[TBL] [Abstract][Full Text] [Related]
8. The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo.
Ng HL; Lu A; Lin G; Qin L; Yang Z
Int J Mol Sci; 2014 Dec; 16(1):230-55. PubMed ID: 25547490
[TBL] [Abstract][Full Text] [Related]
9. The interrelationship between HER2 and CASP3/8 with apoptosis in different cancer cell lines.
Arman K; Ergün S; Temiz E; Öztuzcu S
Mol Biol Rep; 2014 Dec; 41(12):8031-6. PubMed ID: 25189649
[TBL] [Abstract][Full Text] [Related]
10. The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing.
Werner D; Battmann A; Steinmetz K; Jones T; Lamb T; Martinez M; Altmannsberger HM; Al-Batran SE
J Transl Med; 2014 Jun; 12():160. PubMed ID: 24906218
[TBL] [Abstract][Full Text] [Related]
11. The aqueous extract of Ficus religiosa induces cell cycle arrest in human cervical cancer cell lines SiHa (HPV-16 Positive) and apoptosis in HeLa (HPV-18 positive).
Choudhari AS; Suryavanshi SA; Kaul-Ghanekar R
PLoS One; 2013; 8(7):e70127. PubMed ID: 23922932
[TBL] [Abstract][Full Text] [Related]
12. In vivo targeting of HER2-positive tumor using 2-helix affibody molecules.
Ren G; Webster JM; Liu Z; Zhang R; Miao Z; Liu H; Gambhir SS; Syud FA; Cheng Z
Amino Acids; 2012 Jul; 43(1):405-13. PubMed ID: 21984380
[TBL] [Abstract][Full Text] [Related]
13. EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.
Iida K; Nakayama K; Rahman MT; Rahman M; Ishikawa M; Katagiri A; Yeasmin S; Otsuki Y; Kobayashi H; Nakayama S; Miyazaki K
Br J Cancer; 2011 Jul; 105(3):420-7. PubMed ID: 21730982
[TBL] [Abstract][Full Text] [Related]
14. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.
Moelans CB; van Diest PJ; Milne AN; Offerhaus GJ
Patholog Res Int; 2010 Dec; 2011():674182. PubMed ID: 21188213
[TBL] [Abstract][Full Text] [Related]
15. Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer.
Cooke SL; Temple J; Macarthur S; Zahra MA; Tan LT; Crawford RA; Ng CK; Jimenez-Linan M; Sala E; Brenton JD
Br J Cancer; 2011 Jan; 104(2):361-8. PubMed ID: 21063398
[TBL] [Abstract][Full Text] [Related]
16. Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection.
Shukla S; Shishodia G; Mahata S; Hedau S; Pandey A; Bhambhani S; Batra S; Basir SF; Das BC; Bharti AC
Mol Cancer; 2010 Oct; 9():282. PubMed ID: 20977777
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of MUC4 in cervical squamous cell carcinoma: pathologic significance.
Munro EG; Jain M; Oliva E; Kamal N; Lele SM; Lynch MP; Guo L; Fu K; Sharma P; Remmenga S; Growdon WB; Davis JS; Rueda BR; Batra SK
Int J Gynecol Pathol; 2009 Mar; 28(2):127-33. PubMed ID: 19188823
[TBL] [Abstract][Full Text] [Related]
18. Deletion in chromosome 11 and Bcl-1/Cyclin D1 alterations are independently associated with the development of uterine cervical carcinoma.
Singh RK; Dasgupta S; Bhattacharya N; Chunder N; Mondal R; Roy A; Mandal S; Roychowdhury S; Panda CK
J Cancer Res Clin Oncol; 2005 Jun; 131(6):395-406. PubMed ID: 15856299
[TBL] [Abstract][Full Text] [Related]
19. Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma.
Rao PH; Arias-Pulido H; Lu XY; Harris CP; Vargas H; Zhang FF; Narayan G; Schneider A; Terry MB; Murty VV
BMC Cancer; 2004 Feb; 4():5. PubMed ID: 15018632
[TBL] [Abstract][Full Text] [Related]
20. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome.
Narayan G; Arias-Pulido H; Koul S; Vargas H; Zhang FF; Villella J; Schneider A; Terry MB; Mansukhani M; Murty VV
Mol Cancer; 2003 May; 2():24. PubMed ID: 12773202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
